Chemotherapy Induced Peripheral Neuropathy in breast cancer Patients

Gharib Fawi, Hazem K Elhewag, Mohamed Nasreldin Thabit, Manar Hamza Sayed

*Department of Neurology and Psychiatry, Faculty of Medicine, Sohag University

Abstract
Peripheral neuropathy induced by chemotherapy is considered the most common neurological disorder associated with chemotherapy. Different sites are involved in the mechanism of chemotherapy induced peripheral neuropathy and considered multifactorial. 68% of cases develop CIPN during the first month following the start of chemotherapy, 60% of cases develop CIPN within 3 months after chemotherapy and only 30% after 6 months. CIPN is caused by chemotherapeutic agents which include taxanes, platinum analogs, and vinca alkaloids. The clinical presentation of CIPN includes multiple symptoms that may cause functioning impairment and may require reduction of the dose of chemotherapy. CIPN considered a common sequel of different agents of chemotherapy and may last from months to years after chemotherapy completion. CIPN can be diagnosed by a detailed history and clinical examination. Clinical examination of a patient with CIPN can be done by the use of nerve conduction studies. Antidepressant includes tricyclic antidepressants and serotonin-noradrenaline reuptake inhibitors are common drugs used for CIPN. Patients may require reductions, substitutions, or stopping of chemotherapeutic agents according to the severity of symptoms.

Keywords: chemotherapy, peripheral Neuropathy, breast cancer, nerve conduction studies

Introduction:
Breast cancer in women is considered the second most common cancer in the world with, more than 2 million newly diagnosed cases in 2020. Recently, the incidence rates of breast cancer have been increased due to improvement in assessment of risk factors, registration of cases, and early detection of cancer. The survival rate is according to stage and molecular subtype.[1]
Chemotherapy is classified into neoadjuvant and adjuvant chemotherapy and used in most cases of breast cancer. Choose the most appropriate one as regards the characteristics of cancer.

The best for locally advanced and inflammatory breast can-cers is the neoadjuvant chemotherapy, especially in large breast tumors to allow breast conserving surgery. Also, used in small tumors with worse prog-nostic subtypes such as HER2 and triple-negative breast cancers, which can be administered intravenously or orally.[2] CIPN is considered frequent neurological disor-der of oral and intra-venous chemother-apy occur in patients with breast cancer. Most common che-motherapeutic agents that cause CIPN include taxanes, platinum analogs, and vinca
alkaloids. Common presentations are, tingling, numbness, burning pain, and impaired sensory functions in both upper and lower limbs. Onset of pain symptoms can be acute (within hours) or chronic (after several doses of chemotherapy) [3]. CIPN presents with multiple symptoms and may lead to long-term functional impairment that requires a reduction of the dose of a chemotherapeutic agent. Although 30–40% of patients have chronic symptoms, CIPN may improve after the stoppage of the chemotherapeutic agent [4]. Clinical practice guidelines found that there are no agents that are highly recommended to prevent or treat CIPN [5]. Common drugs used for CIPN are serotonin-noradrenaline reuptake inhibitors, tricyclic antidepressants, and pregabalin. Many clinical trials have been conducted to investigate the effectiveness of approved drugs against CIPN [6]. Most of these drugs have poor efficacy, except for duloxetine [7].

**Prevalence of CIPN**
The prevalence of CIPN is usually affected by the type of chemotherapy, dose, and treatment duration [8]. 68% of cases develop CIPN one month following the start of chemotherapy, 60% of cases develop CIPN within 3 months after chemotherapy, and only 30% of cases six months following treatment. [9]. Symptoms of neuropathy usually last for 6 months or more even, after the stoppage of chemotherapy [10]. 42% of patients developed symptoms of CIPN within 2 years after use of docetaxel treatment [11].

**Mechanisms of CIPN**:
The mechanism of the pathogenesis of CIPN is multifactorial. Chemotherapy develops toxic effects on several sites of nervous system which include myelin sheaths, axonal components and dorsal root ganglion especially sensory affected [15].

cells. Pathways are started by triggering of degeneration followed by pro-inflammatory cytokine release and alteration of excitability of neurons followed by loss of epidermal fiber [12]. The effects of oxaliplatin and cisplatin have effects similar to those of other platinum-containing compounds that disturb the proliferation of cancer cells by the formation of deoxyribonucleic acid (DNA)-platinum compounds. The platinum complex is formed of two chloride atoms which will be hydrolyzed after entrance to the cell and then transformed into a strong electrophile. Adenine and guanine bases of DNA are then cross linked by activated cisplatin, which will disturb messenger ribonucleic acid (mRNA) transcription and division of the cell [13].

**Clinical features of CIPN:**
Sensory neuropathy is the most predominant presentation of CIPN that may be associated with motor or autonomic symptom. Sensory neuropathy can accompanied by positive and negative symptoms. CIPN is predominantly sensory neuropathy in the form of sensory abnormalities in the stocking/glove distribution. Mild motor symptoms may occur but are less common. Rarely, autonomic impairment may be developed. The sensory abnormalities usually start in the lower extremities and then the upper extremities, but in 68% of the patients, they start in the upper and lower limbs simultaneously [14]. Paclitaxel and vincristine most frequently develop motor types of neuropathy. Impairment of the autonomic nervous system is a common adverse effect of use vinca alkaloids agent and presented by gastrointestinal, genitourinary and cardiovascular disturbance. (Fig 1). Clinical presentation of CIPN as regards the type of peripheral nerves
Diagnostics
A baseline neurological examination should be done before the start of any neurotoxic agent for each patient with cancer to detect patients with a high risk of peripheral neuropathy [17]. History taking and clinical assessment are recommended when peripheral neuropathy is suspected. Clinical assessment of CIPN can be done by nerve conduction studies [18]. Clinically-assessed neuropathy scores have been used to confirm diagnosis, which include the Total Neuropathy Score. This questionnaire used for assessment of symptoms includes the QLQ-CIPN20, which forms an ordinal 1–4 scale that measure 20 items (1, not at all; 4, very much) [19]. TNS can assess the severity and is considered a reliable tool [20]. Other versions, which include the TNS-reduced scale and theTNS-clinical scale can evaluate patients with neuropathy [21]. Pain screening can be done by Pain DETECT, which is specifically used for the detection of pain in clinical [22].

Treatment of CIPN:
Clinical studies consider antidepressants, anticonvulsants, minerals, and vitamins as efficient compounds in the prevention of neuropathy induced by chemotherapy [23]. Some studies suggest that cooling of extremities can be used as a method to reduce the severity of symptoms, especially in patients receiving taxanes [24]. Regular exercises include mobility recommended before initiation of neurotoxic agent therapies as physical exercise may minimize symptoms of neuropathy [25]. Non-pharmacological and pharmacological treatments are recommended by guidelines for manifest CIPN. The best treatment choice for pain includes gabapentin and antidepressants (SSRIs and tricyclic antidepressants). Existing guidelines recommend only duloxetine to treat neuropathy induced by chemotherapeutic agents [26].

Conclusion
CIPN represents a common neurological disorder in cancer patients. Chemotherapy-induced peripheral neuropathy is a common toxicity caused by cytotoxic agents, including platinums, taxanes, and vinca alkaloids. These agents result in pathologic insults to neurons that may last for several years after the stoppage of cytotoxic agent. Common presentations are tingling, numbness, burning pain, and impaired sensory functions in both hands and/or feet. Neurologic tests, including nerve conduction studies can be used for diagnosis. Chemotherapy-induced peripheral neuropathy can markedly impair functioning and the outcome of cancer. Limitation of the dose of a chemotherapeutic agent may be required in patients with CIPN.
**References:**

1. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021 Aug 25; 13(17):4287.

2. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2005 Aug; 11(16):5678-5685.

3. Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA: a Cancer Journal for Clinicians. 2013 Nov-Dec; 63(6):419-437.

4. Maihöfner C, Diel I, Tesch H, Quandel T, Baron R. Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin. Support Care Cancer. 2021 Aug; 29(8):4223-4238.

5. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2020 Oct; 38(28):3325-3348.

6. Cavaletti G, Marmiroli P. Management of Oxaliplatin-Induced Peripheral Sensory Neuropathy. Cancers (Basel). 2020 May 27; 12(6):1370.

7. Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Journal of Clinical Oncology. J. Clin. Oncol. 2020 Oct; 38(28):3325-3348.

8. Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA: a Cancer Journal for Clinicians. 2013 Nov-Dec; 63(6):419-437.

9. Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014 Dec; 155(12):2461-2470.

10. Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J. Chemotherapy-Associated Peripheral Neuropathy in Patients with Early-Stage Breast Cancer: A Systematic Review. J Natl Cancer Inst. 2018 Feb 1; 110(2):djx140.

11. Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018 Feb 1; 110(2):djx162.

12. Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treatment Reviews. 2014 Aug; 40(7):872-882.

13. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014 Oct 5; 740:364-78.

14. Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B, Abrams G, Chen LM, Kober KM, Conley YP, Chesney M, Bolla K, Mauisisa G, Mazor M, Wong M, Schumacher M, Levine JD. Chemotherapy-Induced Neuropathy in Cancer Survivors. J Pain Symptom Manage. 2017 Aug; 54(2):204-218.e2.

15. Maihöfner C, Diel I, Tesch H, Quandel T, Baron R. Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin. Support Care Cancer. 2021 Aug; 29(8):4223-4238.
16. Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA: Cancer J Clin. 2013 Nov-Dec; 63(6):419-437., 2013. 63 (6), 419–437.

17. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2014 Jun; 32(18):1941-1967.

18. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology. 2006 Feb; 33(1):15-49.

19. Postma TJ, Aaronson NK, Heimans JJ, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. European Journal of Cancer (Oxford, England: 1990). 2005 May; 41(8):1135-1139.

20. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. Journal of the Peripheral Nervous System: JPNS. 2007 Sep; 12(3):210-215.

21. Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-Induced Peripheral Neuropathy assessment: a critical revision of the currently available tools. European Journal of Cancer (Oxford, England: 1990). 2010 Feb; 46(3):479-494.

22. Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006 Oct; 22(10):1911-1920.

23. Kachrani R, Santana A, Rogala B, Pawasauskas J. Chemotherapy-Induced Peripheral Neuropathy: Causative Agents, Preventative Strategies, and Treatment Approaches. J Pain Palliat Care Pharmacother. 2020 Sep; 34(3):141-152.

24. Beijers AJM, Bonhof CS, Mols F, et al. Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy. Annals of Oncology: Ann Oncol. 2020 Jan; 31(1):131-136.

25. Zimmer P, Trebing S, Timmers-Trebing U, et al. Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2018 Feb;26(2):615-624 Zimmer P, Trebing S, Timmers-Trebing U, Schenk A, Paust R, Bloch W, Rudolph R, Streckmann F, Baumann FT .Eight-week, multimodal exercise counteracts a progress of chemotherapy-induced peripheral neuropathy and improves balance and strength in metastasized colorectal cancer patients: a randomized controlled trial. Support Care Cancer, 2018 Feb; 26(2):615-624.

26. Hershman DL, Lacchetti C, Loprinzi CL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice. 2014 Nov; 10(6):e421-e424.